enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
Frequently asked questions
What is enGene Holdings Inc. Common Stock (ENGN) current stock price?
As of the latest data, enGene Holdings Inc. Common Stock stock price is $1.72, with a previous close of $1.70. enGene Holdings Inc. Common Stock gained $0.02 in the last trading session, representing a 1.18% increase.
Does enGene Holdings Inc. Common Stock (ENGN) pay dividends?
No. enGene Holdings Inc. Common Stock does not pay a dividend.
